Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients. 2004

Nikolaos E Bonaros, and Alfred Kocher, and Daniela Dunkler, and Michael Grimm, and Andreas Zuckermann, and Jan Ankersmit, and Marek Ehrlich, and Ernst Wolner, and Günther Laufer
Department of Cardiac Surgery, University of Innsbruck, Innsbruck Austria. nikolaos.bonaros@uibk.ac.at

BACKGROUND Seronegative heart transplant recipients who receive an allograft from seropositive donors have a higher risk of developing cytomegalovirus (CMV) disease and cardiac allograft vasculopathy (CAV) and dysfunction. Neither CMV-specific hyperimmune globulin nor ganciclovir as sole CMV prophylaxis is sufficient to prevent CMV disease in high-risk patients. We retrospectively evaluated the efficacy of CMV-hyperimmune globulin with and without ganciclovir in 207 D+/R- heart transplant recipients. METHODS The study population was divided into two groups: Group A was composed of 96 patients who received CMV hyperimmune globulin as sole CMV prophylaxis, and group B was composed of 111 patients who received combined CMV prophylaxis. All recipients were subjected to quadruple cytolytic immunosuppression. Primary and secondary end points included prevention of CMV-associated death, CMV disease and productive infection, CAV, and overall infection. RESULTS There was no difference in overall survival between the two groups. Four patients in the group A died of CMV sepsis, whereas no CMV-associated death was observed in group B (P =0.0326). The actuarial incidence of CMV disease was significantly lower in patients who received double CMV prophylaxis (32.29 vs. 11.71, P =0.0003). Although no difference was observed with regard to productive CMV infection (53.12 vs. 65.77, P =not significant), CAV and overall infection rates were significantly higher in the first group (7.29 vs. 0.9, P =0.0157 and 70.83 vs. 62.16, P =0.03, respectively). CONCLUSIONS Double CMV prophylaxis consisting of CMV hyperimmune globulin and ganciclovir is able to abolish CMV death and prevent CMV disease in high-risk heart transplant recipients. Therefore, the use of a combination regimen is recommended for seronegative recipients with seropositive donors.

UI MeSH Term Description Entries
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D007136 Immunoglobulins Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses. Globulins, Immune,Immune Globulin,Immune Globulins,Immunoglobulin,Globulin, Immune
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

Nikolaos E Bonaros, and Alfred Kocher, and Daniela Dunkler, and Michael Grimm, and Andreas Zuckermann, and Jan Ankersmit, and Marek Ehrlich, and Ernst Wolner, and Günther Laufer
November 2001, Transplantation,
Nikolaos E Bonaros, and Alfred Kocher, and Daniela Dunkler, and Michael Grimm, and Andreas Zuckermann, and Jan Ankersmit, and Marek Ehrlich, and Ernst Wolner, and Günther Laufer
April 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation,
Nikolaos E Bonaros, and Alfred Kocher, and Daniela Dunkler, and Michael Grimm, and Andreas Zuckermann, and Jan Ankersmit, and Marek Ehrlich, and Ernst Wolner, and Günther Laufer
October 1990, Transplantation proceedings,
Nikolaos E Bonaros, and Alfred Kocher, and Daniela Dunkler, and Michael Grimm, and Andreas Zuckermann, and Jan Ankersmit, and Marek Ehrlich, and Ernst Wolner, and Günther Laufer
April 2009, Transplant infectious disease : an official journal of the Transplantation Society,
Nikolaos E Bonaros, and Alfred Kocher, and Daniela Dunkler, and Michael Grimm, and Andreas Zuckermann, and Jan Ankersmit, and Marek Ehrlich, and Ernst Wolner, and Günther Laufer
August 1993, Transplantation proceedings,
Nikolaos E Bonaros, and Alfred Kocher, and Daniela Dunkler, and Michael Grimm, and Andreas Zuckermann, and Jan Ankersmit, and Marek Ehrlich, and Ernst Wolner, and Günther Laufer
August 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society,
Nikolaos E Bonaros, and Alfred Kocher, and Daniela Dunkler, and Michael Grimm, and Andreas Zuckermann, and Jan Ankersmit, and Marek Ehrlich, and Ernst Wolner, and Günther Laufer
June 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Nikolaos E Bonaros, and Alfred Kocher, and Daniela Dunkler, and Michael Grimm, and Andreas Zuckermann, and Jan Ankersmit, and Marek Ehrlich, and Ernst Wolner, and Günther Laufer
June 1989, Transplantation proceedings,
Nikolaos E Bonaros, and Alfred Kocher, and Daniela Dunkler, and Michael Grimm, and Andreas Zuckermann, and Jan Ankersmit, and Marek Ehrlich, and Ernst Wolner, and Günther Laufer
December 1998, Transplantation proceedings,
Nikolaos E Bonaros, and Alfred Kocher, and Daniela Dunkler, and Michael Grimm, and Andreas Zuckermann, and Jan Ankersmit, and Marek Ehrlich, and Ernst Wolner, and Günther Laufer
October 1995, Transplantation proceedings,
Copied contents to your clipboard!